{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:07:31Z","timestamp":1776859651504,"version":"3.51.2"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IMK Almene","award":["102-0489\/13-3000"],"award-info":[{"award-number":["102-0489\/13-3000"]}]},{"name":"Savv\u00e6rksejer Ivita and Jeppe Juhl Foundation,","award":["102-5212\/18-3000"],"award-info":[{"award-number":["102-5212\/18-3000"]}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["DK001"],"award-info":[{"award-number":["DK001"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["DCSR010"],"award-info":[{"award-number":["DCSR010"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kathrine and Vigo Skovgaard Foundation","award":["KVSF010"],"award-info":[{"award-number":["KVSF010"]}]},{"name":"the Danish Strategic Research Counsel","award":["DSRC010"],"award-info":[{"award-number":["DSRC010"]}]},{"name":"I.M. Daehnfeldt Foundation.","award":["IMDF010"],"award-info":[{"award-number":["IMDF010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan containing therapy in first-line setting. Among these, 108 were eligible for analyses. Immunohistochemistry (IHC) analyses were performed on the primary tumor tissue in order to classify samples as high or low presence of ABCG2 protein. Data were then associated with patient outcome (objective response (OR), progression free survival (PFS) and overall survival (OS)). ABCG2 protein expression in the basolateral membrane was high (score 3+) in 33% of the patients. Exploratory analyses revealed a significant interaction between ABCG2 score, adjuvant treatment and OR (p = 0.041) in the 101 patients with evaluable disease. Patients with low ABCG2 (score 0\u20132) and no prior adjuvant therapy had a significantly higher odds ratio of 5.6 (Confidence Interval (CI) 1.68\u201318.7; p = 0.005) for obtaining OR. In contrast, no significant associations between ABCG2 expression and PFS or OS were found. These results suggest that measurement of the ABCG2 drug efflux pump might be used to select patients with mCRC for irinotecan treatment. However, additional studies are warranted before conclusions regarding a clinical use can be made. Moreover, patients with high ABCG2 immunoreactivity could be candidates for specific ABCG2 inhibition treatment in combination with irinotecan.<\/jats:p>","DOI":"10.3390\/ijms21145027","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:22:02Z","timestamp":1594981322000},"page":"5027","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer"],"prefix":"10.3390","volume":"21","author":[{"given":"Jesper Andreas","family":"Palshof","sequence":"first","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Natasha","family":"Cederbye","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, Section for Molecular Disease Biology University of Copenhagen, 2200 N Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrid Vilma Solyom","family":"H\u00f8gdall","sequence":"additional","affiliation":[{"name":"Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-0541","authenticated-orcid":false,"given":"Tim Svenstrup","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-4794","authenticated-orcid":false,"given":"Dorte","family":"Linnemann","sequence":"additional","affiliation":[{"name":"Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sune Boris","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen \u00d8, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-4828","authenticated-orcid":false,"given":"Jan","family":"Stenvang","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, Section for Molecular Disease Biology University of Copenhagen, 2200 N Copenhagen, Denmark"},{"name":"Scandion Oncology, Fruebjergvej 3, DK-2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ib Jarle","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny Vittrup","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, Section for Molecular Disease Biology University of Copenhagen, 2200 N Copenhagen, Denmark"},{"name":"Scandion Oncology, Fruebjergvej 3, DK-2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aalborg University Hospital, Hobrovej 18-22, DK-9100 Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte Martine","family":"Viuff","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, Section for Molecular Disease Biology University of Copenhagen, 2200 N Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorte Lisbet","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer J. Int. Du Cancer"},{"key":"ref_2","first-page":"iii1","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Cervantes","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2011.36.0354","article-title":"American Society of Clinical O: American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays","volume":"29","author":"Burstein","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1476-5381.2010.01177.x","article-title":"The ABCG family of membrane-associated transporters: You don\u2019t have to be big to be mighty","volume":"164","author":"Kerr","year":"2011","journal-title":"Br. J. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-60761-416-6_12","article-title":"Impact of breast cancer resistance protein on cancer treatment outcomes","volume":"596","author":"Ross","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.molonc.2015.02.008","article-title":"Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance","volume":"9","author":"Jensen","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_9","first-page":"1","article-title":"Human ABCG2: Structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"ref_10","first-page":"935","article-title":"Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918","volume":"7","author":"Maliepaard","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.20032","article-title":"ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases","volume":"109","author":"Candeil","year":"2004","journal-title":"Int. J. Cancer J. Int. Du Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","article-title":"Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3","volume":"27","author":"Labianca","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Stenvang, J., Budinska, E., van Cutsem, E., Bosman, F., Popovici, V., and Brunner, N. (2020). An Explorative Analysis of ABCG2\/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial. Cancers, 12.","DOI":"10.3390\/cancers12040977"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Nielsen, D.L., Palshof, J.A., Brunner, N., Stenvang, J., and Viuff, B.M. (2017). Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091926"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: A perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26997","DOI":"10.1038\/srep26997","article-title":"Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue","volume":"6","author":"Cederbye","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15767","DOI":"10.3390\/ijms150915767","article-title":"CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen","volume":"15","author":"Silvestris","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.7150\/jca.12606","article-title":"ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer","volume":"6","author":"Trumpi","year":"2015","journal-title":"J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3892\/ol.2016.4937","article-title":"ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan","volume":"12","author":"Tuy","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_24","first-page":"845","article-title":"Expression of ABCG2 and its significance in colorectal cancer","volume":"11","author":"Liu","year":"2010","journal-title":"Asian Pac. J. Cancer Prev. Apjcp"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-130344","article-title":"Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival","volume":"13","author":"Wang","year":"2013","journal-title":"Cancer Biomark."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-15-0561","article-title":"DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II\/III Colon Cancer","volume":"22","author":"Nygard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4196\/kjpp.2012.16.1.11","article-title":"Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells","volume":"16","author":"Yi","year":"2012","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.3748\/wjg.v19.i39.6630","article-title":"Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2017.35.4_suppl.591","article-title":"ABCG2 and TOP1 mRNA expression as predictive biomarkers for adjuvant FOLFIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial","volume":"35","author":"Brunner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nikas, I.P., Themistocleous, S.C., Paschou, S.A., Tsamis, K.I., and Ryu, H.S. (2019). Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. Cells, 9.","DOI":"10.3390\/cells9010019"},{"key":"ref_31","unstructured":"Bergmann, T.K., Stage, T.B., Stenvang, J., Christophersen, P., Jacobsen, T.A., Roest, N.L., Vestlev, P.M., and Br\u00fcnner, N. Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers. Basic Clin. Pharmacol. Toxicol., Available online: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/bcpt.13466."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Altman, D.G., McShane, L.M., Sauerbrei, W., and Taube, S.E. (2012). Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. BMC Med., 10.","DOI":"10.1186\/1741-7015-10-51"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: A practical approach","volume":"25","author":"Ruschoff","year":"2012","journal-title":"Mod. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:13Z","timestamp":1760176153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21145027"],"URL":"https:\/\/doi.org\/10.3390\/ijms21145027","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}